Drug Profile
ATA 188
Alternative Names: Allogeneic ATA 188; Allogeneic EBV-directed T-cell therapy; ATA-188; EBV-CTLs; EBV-targeted T-cell; Epstein-Barr Virus-directed cytotoxic T lymphocytes; Off-the-shelf ATA188Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Atara Biotherapeutics
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Multiple sclerosis
Most Recent Events
- 17 Jan 2024 Atara Biotherapeutics terminates a phase I/II EMBOLD trial in Multiple sclerosis (Treatment-experienced) in USA, Australia, and Canada (IV), due to the primary endpoint not being achieved (NCT03283826)
- 11 May 2023 9388628: No updates
- 26 Oct 2022 Updated efficacy data from a phase I/II EMBOLD trial in Multiple sclerosis presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2022)